MENU
+Compare
EMBC
Stock ticker: NASDAQ
AS OF
Oct 10, 12:26 PM (EDT)
Price
$13.20
Change
-$0.39 (-2.87%)
Capitalization
808.26M

EMBC stock forecast, quote, news & analysis

Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes... Show more

EMBC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. EMBC showed earnings on August 08, 2025. You can read more about the earnings report here.
Interact to see
Advertisement
A.I.Advisor
a Summary for EMBC with price predictions
Oct 09, 2025

EMBC's RSI Indicator recovers from overbought zone

The 10-day RSI Indicator for EMBC moved out of overbought territory on September 12, 2025. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 16 instances where the indicator moved out of the overbought zone. In of the 16 cases the stock moved lower in the days that followed. This puts the odds of a move down at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 19, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on EMBC as a result. In of 63 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for EMBC turned negative on September 04, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 32 similar instances when the indicator turned negative. In of the 32 cases the stock turned lower in the days that followed. This puts the odds of success at .

EMBC moved below its 50-day moving average on October 09, 2025 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where EMBC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

The 50-day moving average for EMBC moved above the 200-day moving average on October 03, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where EMBC advanced for three days, in of 193 cases, the price rose further within the following month. The odds of a continued upward trend are .

EMBC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 97 cases where EMBC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (11.089). P/E Ratio (9.570) is within average values for comparable stocks, (54.664). EMBC's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.737). EMBC has a moderately high Dividend Yield (0.044) as compared to the industry average of (0.016). P/S Ratio (0.724) is also within normal values, averaging (14.380).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. EMBC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EMBC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.

A.I.Advisor
published Dividends

EMBC paid dividends on September 15, 2025

Embecta Corp EMBC Stock Dividends
А dividend of $0.15 per share was paid with a record date of September 15, 2025, and an ex-dividend date of August 29, 2025. Read more...
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Intuitive Surgical (NASDAQ:ISRG), Align Technology (NASDAQ:ALGN).

Industry description

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

Market Cap

The average market capitalization across the Pharmaceuticals: Other Industry is 11.22B. The market cap for tickers in the group ranges from 246 to 160.63B. ISRG holds the highest valuation in this group at 160.63B. The lowest valued company is PEMTF at 246.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Other Industry was -2%. For the same Industry, the average monthly price growth was 0%, and the average quarterly price growth was 15%. FEMY experienced the highest price growth at 56%, while TUTH experienced the biggest fall at -48%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Other Industry was -20%. For the same stocks of the Industry, the average monthly volume growth was -29% and the average quarterly volume growth was -40%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 56
P/E Growth Rating: 65
Price Growth Rating: 58
SMR Rating: 81
Profit Risk Rating: 91
Seasonality Score: 21 (-100 ... +100)
View a ticker or compare two or three
EMBC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry PharmaceuticalsOther

Profile
Fundamentals
Details
Industry
N/A
Address
300 Kimball Drive
Phone
+1 862 401-0000
Employees
2200
Web
https://www.embecta.com